MarketPeel
Insider Trading Intelligence
GZ

Greg Zante

VKTX
CHIEF FINANCIAL OFFICER · VIKING THERAPEUTICS, INC. · CIK 0001264949
FILING MIX · LIFETIME42%/58%
BUYS
44
SELLS
62
TOTAL VALUE
$34.33M
COMPANIES
1
ACTIVE SINCE
Jan 2021
HOLDINGS NOW
212,204
AVG SELL PX
$36.51
TRADE KIND
SHOWING 106 / 106
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
29 backtested trades · 8 horizons · 21 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Greg Zante, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d29+82.76%-4.08%-0.53%-3.55%-5.11%
14d29+58.62%-3.74%+1.35%-5.09%-0.57%
30d29+62.07%-5.56%+1.97%-7.53%-7.80%
60d29+51.72%+0.14%+3.23%-3.08%-4.87%
90d29+72.41%-10.07%+3.18%-13.25%-30.46%
180d29+79.31%-23.02%+5.48%-28.49%-40.93%
1y29(5 pending)+70.83%+37.16%+19.81%+17.35%-65.35%
2y29(16 pending)+53.85%-7.94%+38.47%-46.41%-74.68%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
VKTX · 212,204 shares · as of Jul 29, 2026
070,263140,527210,790281,05320222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 44 buys / 62 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
21,217$33.47$710.1K212,204Jul 29, 2026Jul 29, 2026View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,667233,421Jul 28, 2026Jul 29, 2026View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
13,900$33.38$464.0K201,671Jan 5, 2026Jan 5, 2026View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
31,961$32.30$1.03M215,571Jan 5, 2026Jan 5, 2026View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,500$32.09$48.1K189,891Jan 5, 2026Jan 5, 2026View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
10,300$34.24$352.6K191,371Jan 5, 2026Jan 5, 2026View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
91,00091,000Jan 2, 2026Jan 5, 2026View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
41,000215,483Jan 2, 2026Jan 5, 2026View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
32,049247,532Jan 2, 2026Jan 5, 2026View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
6,185$35.00$216.5K173,592Oct 28, 2025Oct 28, 2025View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,117179,777Oct 27, 2025Oct 28, 2025View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,266$27.76$118.4K168,660Jul 3, 2025Jul 3, 2025View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,667172,926Jul 2, 2025Jul 3, 2025View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,700$43.32$203.6K165,259Jan 6, 2025Jan 6, 2025View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
45,609$42.69$1.95M169,959Jan 6, 2025Jan 6, 2025View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,667215,568Jan 3, 2025Jan 6, 2025View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
44,533193,901Jan 3, 2025Jan 6, 2025View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,20037,200Jan 3, 2025Jan 6, 2025View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,967$80.65$642.5K150,572Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
12,750$7.77$99.1K199,802Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
9,265$76.94$712.8K203,496Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
4,251$4.68$19.9K204,053Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,206$81.44$98.2K149,366Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
23,082$77.68$1.79M180,414Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
49,672$74.56$3.70M231,381Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,2510Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
18,620$75.79$1.41M212,761Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
51,000$8.52$434.5K281,053Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
26,0000Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
51,000153,000Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
15,825$78.69$1.25M164,589Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
26,000$5.80$150.8K230,053Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
6,050$79.78$482.7K158,539Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
12,7500Oct 28, 2024Oct 28, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,974$57.71$171.6K187,552Jul 30, 2024Jul 31, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
500$58.71$29.4K187,052Jul 30, 2024Jul 31, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
12,662$56.96$721.2K190,526Jul 30, 2024Jul 31, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,667203,188Jul 29, 2024Jul 31, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,667181,521Jul 29, 2024Jul 31, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,101$73.49$227.9K238,509May 3, 2024May 3, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
30,000$4.88$146.4K241,610May 3, 2024May 3, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
30,00060,000May 3, 2024May 3, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
4,249$4.68$19.9K211,610May 3, 2024May 3, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
847$76.07$64.4K174,854May 3, 2024May 3, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,2494,251May 3, 2024May 3, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
45,570$74.44$3.39M192,939May 3, 2024May 3, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
17,238$75.49$1.30M175,701May 3, 2024May 3, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,667223,971Mar 27, 2024Mar 27, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
16,610$83.34$1.38M207,361Mar 27, 2024Mar 27, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,667212,397Mar 1, 2024Mar 4, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
20,093$85.22$1.71M192,304Mar 1, 2024Mar 4, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
15,000$17.90$268.5K180,730Jan 4, 2024Jan 4, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
13,872$18.58$257.7K195,730Jan 4, 2024Jan 4, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
28,334188,724Jan 3, 2024Jan 4, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,000240,491Jan 3, 2024Jan 4, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
155,000155,000Jan 3, 2024Jan 4, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
18,233$17.40$317.3K170,491Jan 3, 2024Jan 4, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
30,889$17.40$537.5K209,602Jan 3, 2024Jan 4, 2024View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,5000Apr 17, 2023Apr 18, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,500$20.00$150.0K149,279Apr 17, 2023Apr 18, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
7,500$13.07$98.0K156,779Apr 17, 2023Apr 18, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
4,097$7.77$31.8K190,823Apr 12, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
41,544$18.00$747.8K149,279Apr 12, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,09712,750Apr 12, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
37,44726,000Apr 12, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
37,447$5.80$217.2K186,726Apr 12, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
3,242$7.77$25.2K152,521Apr 11, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
14,55363,447Apr 11, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
30,00090,000Apr 11, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
14,553$5.80$84.4K205,574Apr 11, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,24216,847Apr 11, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
30,000$4.88$146.4K191,021Apr 11, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
56,295$18.00$1.01M149,279Apr 11, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
8,5008,500Apr 11, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
8,500$4.68$39.8K161,021Apr 11, 2023Apr 13, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
56,667204,445Apr 3, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
30,911$7.77$240.2K178,689Apr 3, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
30,911$18.00$556.4K147,778Apr 3, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
30,9110Apr 3, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
55,166$17.57$969.3K149,279Apr 3, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
32,0000Mar 30, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
12,2500Mar 30, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
12,250$4.65$57.0K271,307Mar 30, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
32,000$8.52$272.6K217,057Mar 30, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
42,000$7.69$323.0K259,057Mar 30, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
131,029$17.00$2.23M147,778Mar 30, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,5000Mar 30, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
7,500$4.12$30.9K278,807Mar 30, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
42,0000Mar 30, 2023Apr 3, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
20,708$8.42$174.4K185,057Jan 4, 2023Jan 4, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
23,933$8.52$203.9K205,765Jan 3, 2023Jan 4, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
204,000204,000Jan 3, 2023Jan 4, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
90,667229,698Jan 3, 2023Jan 4, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,233158,728Dec 30, 2022Jan 4, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
19,697$9.40$185.2K139,031Dec 30, 2022Jan 4, 2023View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
8,835$4.62$40.8K136,304Jan 4, 2022Jan 5, 2022View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
120,000120,000Jan 3, 2022Jan 5, 2022View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
53,333145,139Jan 3, 2022Jan 5, 2022View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,097$4.88$15.1K91,806Jan 3, 2022Jan 5, 2022View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,66796,791Sep 28, 2021Sep 30, 2021View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,306$6.50$15.0K94,485Sep 28, 2021Sep 30, 2021View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
808$6.68$5.4K89,751Jan 19, 2021Jan 19, 2021View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,78393,346Jan 4, 2021Jan 6, 2021View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
78,00078,000Jan 4, 2021Jan 6, 2021View →
VKTX
VIKING THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
64,66786,563Jan 4, 2021Jan 6, 2021View →
VKTX
VIKING THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,787$5.80$16.2K90,559Jan 4, 2021Jan 6, 2021View →
Other insiders · VKTX
Loading peer insiders…
About this filer
CIK 0001264949
ROLE
Chief Financial Officer
PRIMARY
VKTX
COMPANIES
1
ACTIVE SINCE
Jan 2021
MARKETPEEL · /INSIDER/0001264949DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback